Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Novel Pharmacological Therapy for Obstructive Sleep Apnea
Sponsor: Brigham and Women's Hospital
Summary
A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains elusive. Here the investigators study the effect on sleep apnea severity of a combination of pharmacological agents (atomoxetine and oxybutynin, "AtoOxy") over a 1 month period of time. The current study will answer the following questions: Does ongoing, repeated-dose administration of atomoxetine-plus-oxybutynin (referred to as "AtoOxy") improve OSA severity, and do patients exhibit signs of symptomatic relief? Most importantly, which phenotypic subgroup of patients preferentially benefit from this intervention?
Key Details
Gender
All
Age Range
21 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
117
Start Date
2019-09-03
Completion Date
2023-09-07
Last Updated
2026-07-02
Healthy Volunteers
No
Conditions
Interventions
Atomoxetine
Atomoxetine 80 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
Oxybutynin
Oxybutynin 5 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
Placebo
Placebo, per mouth, before bed.Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States